Saturday 17 October 2026
Export MRKR’s income statement to Excel — free account
MARKER THERAPEUTICS, INC.
MRKR Healthcare Biotechnology
In the quarter to June 2026, revenue grew 2.75%, EPS grew 69.0% and free cash flow fell 97.8%, each against the same quarter a year earlier.
1.04
0.12
+13.04%
Follow MRKR
MARKER THERAPEUTICS, INC. (MRKR) P/E ratio
MARKER THERAPEUTICS, INC. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 28.0× (March 2017) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| 17 more quarters | Free account |
Against its own ten years
Low 0.0×
High 28.0×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DARE Dare Bioscience, Inc. compare | n/m |
| GTBP GT Biopharma, Inc. compare | n/m |
| MRKR MARKER THERAPEUTICS, INC. | n/m |
| TCRX TScan Therapeutics, Inc. compare | n/m |
| AKTX Akari Therapeutics PLC compare | n/m |
| NCEL NewcelX Ltd. compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | n/m |
| VAXX Vaxxinity, Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | 0.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)